Published on 04/12/2025

Achieving FDA Compliance through Robust Quality and Data Integrity Systems

1. Introduction – Data Integrity as the Core of FDA Trust

Data integrity violations remain among the top causes of FDA Warning Letters.

The agency defines data integrity as ensuring that data are ALCOA+ — Attributable, Legible, Contemporaneous, Original, Accurate, and complete.

Compliance with 21 CFR Part 11 ensures that electronic records and signatures are as reliable as paper documentation.

2. Governance and Organizational Accountability

FDA expects a clear data governance policy assigning ownership of data systems.

Quality units must verify that procedures address access control, audit trail review, and data retention.

Management oversight ensures that electronic systems remain validated throughout their lifecycle.

3. Computer System Validation (CSV) vs. Computer Software Assurance (CSA)

Traditional CSV emphasized exhaustive testing and documentation.

FDA’s new CSA guidance promotes critical thinking — focusing validation effort on high-risk functions impacting product quality.

This shift aligns with modern agile software development while preserving regulatory assurance.

4. Risk-Based Data Integrity Controls

Applying ICH Q9 principles enables prioritization of controls.

For example, systems generating batch release data require real-time audit trail review, while ancillary systems may rely on periodic verification.

Documented risk assessments justify control intensity and inspection readiness.

5.